Abstract:Introduction: Liver transplantation (LT) is a life-saving procedure that resolves complications of cirrhosis. However, the metabolic risk factors for nonalcoholic fatty liver disease (NAFLD) persist and potentially worsen in the post-transplant setting, thereby increasing the risk of liver fibrosis. Liver biopsy is the gold standard to diagnose NAFLD and liver fibrosis, but this procedure is invasive and less than ideal for longitudinal monitoring after LT. We aimed to investigate the association of serum steatosis and fibrosis biomarkers with mortality and graft loss in LT recipients. Methods: We included consecutive adults who received a liver transplant at the MUHC in 2014-2021 and were followed up annually. The outcomes measured were death and graft loss, graft loss being defined as graft failure leading to death or re-transplantation. We assessed the prognostic value of the biomarkers ALT, AST, GGT, AST-to-Platelet Ratio Index (APRI), fibrosis-4 index (FIB-4), and hepatic steatosis index (HSI). Hepatic steatosis was defined as HSI >36, and liver fibrosis was characterized as FIB-4 > 3.64 or APRI > 1. Survival analysis and Generalized Estimating Equation (GEE) models were used to assess the association between the biomarkers and the outcomes. Results: Two hundred nineteen patients were followed for 30 months on average. Graft loss and mortality occurred in 12 patients (9%) and 38 (29.5%) resulting in incidence rates of 29.5 (95% CI 20.9-40.6) and 9.6 (95% CI 5-16.8) per 100 person-years, respectively. Patients who died during the follow-up were older, had an older donor, and had a history of diabetes. On multivariable analysis using the GEE model (see Table 1), higher ALT and higher AST were associated with mortality after adjustment for sex, BMI, age, albumin, and platelets. In the time-to-event analysis, the Kaplan Meier curves showed that APRI >1 could be a potential predictor of mortality (P = 0.0729 see Figure 1). Neither FIB-4 (log-rank, P = 0.199) nor HSI (log-rank, P = 0.919) were associated with mortality. None of the biomarkers or liver transaminases were associated with graft loss. Conclusion: Liver transaminases and the serum fibrosis biomarker APRI are associated with mortality in LT recipients. The hepatic steatosis biomarker HSI does not seem to be valuable in predicting outcomes in this population. None among liver transaminases, steatosis or fibrosis biomarkers predicted graft loss. Table 1. - GEE of liver transaminases on death in LT patients Characteristics Univariate Multi-Variate * Odds Ratio 95% CI P-value Odds Ratio 95% CI P-value ALT Moderate/Severe 0.9999 0.9999–1.0000 0.0931 1.0001 1.0000–1.0002 0.0040 AST Moderate/Severe 1.0000 0.9999–1.0000 0.3934 1.0001 1.0000–1.0001 0.0037 ALP Moderate/Severe 0.9999 0.9996–1.0001 0.2807 1.0000 0.9998–1.0001 0.6113 GGT Moderate/Severe 0.9998 0.9996–1.0000 0.0236 0.9998 0.9997–1.0000 0.0596 Smoking status No 1.00 1.00 Yes 0.921 0.71–1.20 0.5444 0.934 0.74–1.18 0.5649 *multivariate models are adjusted for age, sex, albumin, BMI and platelets. Figure 1.: Kaplan-Meier survival curve in LT patients according to the APRI biomarker.

Temporal evolution of liver function parameters predicts clinical outcome in chronic heart failure patients (Bio-SHiFT study)

Predictive values of three indexes on short-term prognosis in patients with liver failure treated by artificial liver support system

Combined evaluation of liver and kidney function improves prediction of clinical outcome in patients with chronic heart failure and reduced ejection fraction

Prognostic Implication Of Liver Function Tests In Heart Failure With Preserved Ejection Fraction Without Chronic Hepatic Diseases: Insight From Topcat Trial

Patient-specific evolution of renal function in chronic heart failure patients dynamically predicts clinical outcome in the Bio-SHiFT study

Cardiometabolic Biomarkers and Their Temporal Patterns Predict Poor Outcome in Chronic Heart Failure (Bio-SHiFT Study)

HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure

P5405Clinical and prognostic relevance of increased liver stiffness coupled with abnormal liver function tests in decompensated heart failure

Serum Fibrosis and Steatosis Biomarkers for the Prediction of Mortality in Liver Transplant Recipients

Prognostic Utility of Novel Biomarkers in Acute-on-chronic Liver Failure (ACLF) Associated with Hepatitis B: A Multicenter Prospective Study.

Prognostic value of albumin-bilirubin score in patients with chronic heart failure

Serial assessment of biomarkers and heart failure outcomes in patients with atrial fibrillation

Impact of Albumin-bilirubin (ALBI) score on the Prognostic Significance of Patients with Heart Failure:A Retrospective Cohort Study

Abnormal Liver Function Tests Were Related to Short- and Long-Term Prognosis in Critically Ill Patients With Primary Pulmonary Hypertension

Blood Biomarkers Predict 10-Year Clinical Outcomes in Adult Patients With Congenital Heart Disease

Plasma tumour necrosis factor-alpha-related proteins in prognosis of heart failure with pulmonary hypertension

Proteomic biomarkers of recovered heart function

Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT

CARDIAC AND HEPATIC DYSFUNCTION IN HYPERTENSIVE PATIENTS BY ASSOCIATION OF LIVER FIBROSIS INDICES 4 AND 5

Short‐term prognostic implications of serum and urine neutrophil gelatinase‐associated lipocalin in acute heart failure: findings from the AKINESIS study

Early postoperative Fibrinogen-to-Albumin Ratio prognosticate 6-month procedural success in patients undergoing orthotopic heart transplantation